KIR3DL1 Inhibitors
KIR3DL1 inhibitors belong to a distinctive class of compounds designed to modulate the activity of the Killer Cell Immunoglobulin-like Receptor 3DL1 (KIR3DL1), a critical component of the immune system. KIR3DL1 is primarily expressed on the surface of natural killer (NK) cells and a subset of T cells, playing a pivotal role in immune response regulation. These inhibitors are specifically engineered to interfere with the interaction between KIR3DL1 and its ligands, typically human leukocyte antigen (HLA)-B molecules. By disrupting this binding event, KIR3DL1 inhibitors aim to alter the activation threshold of NK cells and T cells, influencing their ability to recognize and target aberrant cells such as infected or cancerous ones.
KIR3DL1 inhibitors often involves small organic compounds that can selectively bind to the extracellular domain of KIR3DL1, obstructing its binding sites and impeding the downstream signaling cascades associated with immune cell activation. Researchers employ various structural modifications and optimization strategies to enhance the binding affinity and specificity of these inhibitors. Understanding the intricate molecular interactions between KIR3DL1 and its ligands is crucial for the rational design of potent inhibitors. As the development of KIR3DL1 inhibitors progresses, their potential impact on modulating immune responses may offer insights into novel approaches for manipulating the immune system in a controlled manner, contributing to advancements in the field of immunomodulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $150.00 $263.00 $518.00 $731.00 $1461.00 | 1 | |
Interferes with DNA synthesis and could reduce the expression of HLA molecules, potentially affecting KIR3DL1 interactions. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Affects the mevalonate pathway and could modulate the expression of HLA molecules, potentially altering KIR3DL1 activity. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $91.00 $255.00 | 32 | |
Alkylates/methylates DNA, which could affect the expression of HLA class I molecules and thus influence KIR3DL1-mediated inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can alter the levels of HLA class I molecules, potentially affecting their interaction with KIR3DL1. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Alters endosomal pH and can affect antigen processing, potentially impacting the expression of HLA molecules and KIR3DL1 interaction. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Affects Golgi function, potentially altering glycosylation and expression of HLA molecules, influencing KIR3DL1 activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium levels and could modulate signaling pathways in NK cells, influencing KIR3DL1 function. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
PKC inhibitor that can alter signaling pathways in NK cells, potentially affecting KIR3DL1-mediated inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Inhibits PKC, which could disrupt signaling pathways in NK cells and impact KIR3DL1 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that can affect NK cell activation and potentially influence KIR3DL1 signaling. | ||||||